GAMBACORTI PASSERINI CARLO

Elli, E., Mauri, M., D’Aliberti, D., Crespiatico, I., Fontana, D., Redaelli, S., et al. (2024). Idiopathic erythrocytosis: a germline disease?. CLINICAL AND EXPERIMENTAL MEDICINE, 24(1) [10.1007/s10238-023-01283-y]. Detail

Rosti, G., Brummendorf, T., Gjertsen, B., Giraldo-Castellano, P., Castagnetti, F., Gambacorti-Passerini, C., et al. (2024). Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study. LEUKEMIA, 38(1), 126-135 [10.1038/s41375-023-02080-y]. Detail

Fontana, D., Malighetti, F., Villa, M., Zambon, A., Gambacorti-Passerini, C., Mologni, L. (2024). Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. LEUKEMIA, 38(8), 1843-1847 [10.1038/S41375-024-02282-Y]. Detail

Crippa, V., Fontana, D., Civettini, I., Mologni, L., Piazza, R., Gambacorti Passerini, C., et al. (2024). Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer. Intervento presentato a: AACR Annual Meeting 2024 - April 5 - 10, 2024, San Diego, Ca, Usa. Detail

Villa, M., Geeta, G., Malighetti, F., Mauri, M., Arosio, G., Cordani, N., et al. (2024). Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma. BRITISH JOURNAL OF CANCER, 131(11), 1781-1795 [10.1038/s41416-024-02881-7]. Detail